InnoSkel is a platform biotech developing gene therapies targeting rare skeletal diseases, notably type 2 collagenopathies. Its lead asset focuses on Spondyloepiphyseal Dysplasia congenita (SEDc), a severe neonatal skeletal disorder, and has shown good efficacy in proof‑of‑concept studies. The company intends to use proceeds to advance multiple assets from its dedicated gene therapy platform toward clinical development. InnoSkel is a spin‑out of the Institut de Biologie Valrose at Inserm and is led by founder and CEO Elvire Gouze. Gouze is a serial entrepreneur and expert in skeletal disorders whose prior venture, TherAchon, was acquired by Pfizer for $810M. The company emphasizes delivering curative treatments where current options are limited to clinical management and surgeries.

Total raised

$24M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2020